Intern - Industrial Trainees in Neuroscience Drug Discovery- University College London

Closing Date
10 Nov 2019
£10.55 per hour
UCL - Alzheimers Research UK - Drug Discovery Institute, London
up to 12 months

The Alzheimer’s Research UK Drug Discovery Institute (ARUK UCL DDI), located at University College London (UCL), is part of a network of world class Drug Discovery Institutes, with the goal of finding new treatments for neurodegenerative disease. 

As part of the Queen Square Institute of Neurology it will be integrated into the world renowned UCL Neuroscience community and will have full access to the leading expertise within the UCL campus. 

Applications are invited from students currently seeking to undertake the “industrial trainee” year of their undergraduate biological science B.Sc. course

You will gain experience of working in a unit which has a focus upon drug discovery. 

You will learn some key molecular and cellular biology techniques necessary for laboratory neuroscience research, and use these skills to enable you to carry out a research project, the topic of which is relevant to one of the key drug discovery projects of the ARUK UCL DDI. 

Applicants should be studying for a BSc in a Biological Science, ideally Neuroscience, with the opportunity to have an industrial trainee year starting summer 2020. 

Previous laboratory experience, perhaps gained through a summer placement, is highly desirable.  They should demonstrate initiative and flexible approach to problem solving, and an ability to work both in a team and independently. 

Posts are available from September 2020, for up to 12 months. The appointed intern will be paid at the London Living Wage rate, which is currently set at £10.55 per hour. 

You should apply for this post by emailing your c.v. and cover letter to Prof Paul Whiting (email: 

We particularly welcome female applicants and those from an ethnic minority, as they are under-represented within UCL at this level.

For more information please click here. 

Contact Details

Prof Paul Whiting (email: